| P50 | author | Che-Ming Teng | Q56996745 |
| | Kuo-Hsiung Lee | Q87895492 |
| P2093 | author name string | Mei-Chuan Chen | |
| | Shiow-Lin Pan | |
| | Szu-Ying Wu | |
| | Jui-Ling Hsu | |
| | Zhi-Yan Xiao | |
| P2860 | cites work | Linkage of ATM to cell cycle regulation by the Chk2 protein kinase | Q22008502 |
| | DNA topoisomerases: structure, function, and mechanism | Q22065417 |
| | Cellular roles of dna topoisomerases: a molecular perspective | Q22121990 |
| | ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage | Q24306743 |
| | Cell cycle, CDKs and cancer: a changing paradigm | Q24314465 |
| | Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes | Q24533892 |
| | ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1 | Q24550952 |
| | Targeting DNA topoisomerase II in cancer chemotherapy | Q24649711 |
| | A model for the mechanism of human topoisomerase I | Q27748893 |
| | DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139 | Q28131715 |
| | Mechanisms of caspase activation | Q28187994 |
| | Etoposide: four decades of development of a topoisomerase II inhibitor | Q28294370 |
| | Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II | Q28473683 |
| | DNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition | Q29400901 |
| | H2AX is required for cell cycle arrest via the p53/p21 pathway | Q30487614 |
| | The plant isoflavenoid genistein activates p53 and Chk2 in an ATM-dependent manner | Q31627070 |
| | Higher expression of topoisomerase II alpha is an independent marker of increased risk of cancer-specific death in patients with clear cell renal cell carcinoma | Q33807370 |
| | DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis | Q33814324 |
| | Rb function in cell-cycle regulation and apoptosis | Q33900128 |
| | Tumor cell death induced by topoisomerase-targeting drugs. | Q34192665 |
| | DNA damage-induced activation of ATM and ATM-dependent signaling pathways | Q34336538 |
| | DNA damage-induced cell-cycle phase regulation of p53 and p21waf1 in normal and ATM-defective cells | Q52552396 |
| | Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide | Q70543495 |
| | Yeast DNA topoisomerase II. An ATP-dependent type II topoisomerase that catalyzes the catenation, decatenation, unknotting, and relaxation of double-stranded DNA rings | Q72926605 |
| | Enhancement of etoposide (VP-16) cytotoxicity by enzymatic and photodynamically induced oxidative stress | Q73162158 |
| | Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses | Q73387126 |
| | Reactive oxygen intermediates are involved in the induction of CD95 ligand mRNA expression by cytostatic drugs in hepatoma cells | Q73836138 |
| | Clinical applications of anticancer drugs targeted to topoisomerase II | Q77333693 |
| | Elevated Akt activation and its impact on clinicopathological features of renal cell carcinoma | Q78835873 |
| | Physalin F induces cell apoptosis in human renal carcinoma cells by targeting NF-kappaB and generating reactive oxygen species | Q34345070 |
| | Reactive oxygen species in cancer cells: live by the sword, die by the sword. | Q34564435 |
| | Topoisomerase poisons activate the transcription factor NF-kappaB in ACH-2 and CEM cells | Q34616111 |
| | DNA and its associated processes as targets for cancer therapy | Q34625003 |
| | Apoptosis induced by topoisomerase inhibitors | Q35137789 |
| | The role of ATM and ATR in DNA damage-induced cell cycle control | Q35573716 |
| | PI3K/Akt signalling pathway and cancer. | Q35692250 |
| | ROS stress in cancer cells and therapeutic implications | Q35781703 |
| | Topoisomerase II and the etiology of chromosomal translocations | Q36542253 |
| | Cellular response to etoposide treatment. | Q36682423 |
| | DNA topoisomerase II, genotoxicity, and cancer | Q36903197 |
| | The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing | Q37108461 |
| | DNA topoisomerase II and its growing repertoire of biological functions. | Q37313703 |
| | Apoptosis and glutathione: beyond an antioxidant. | Q37574928 |
| | DNA topoisomerase II enzymes as molecular targets for cancer chemotherapy | Q37767731 |
| | Targeted therapy for renal cell cancer: current perspectives. | Q37814526 |
| | Quantitative analysis of topoisomerase II alpha and evaluation of its effects on cell proliferation and apoptosis in glioblastoma cancer stem cells | Q39351920 |
| | Synthesis and anticancer effects of some novel pyrazolo[3,4-d]pyrimidine derivatives by generating reactive oxygen species in human breast adenocarcinoma cells | Q39593712 |
| | A Sign Inversion Mechanism for Enzymatic Supercoiling of DNA | Q40262946 |
| | The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy | Q40278749 |
| | Antitumor agents. 234. Design, synthesis, and biological evaluation of novel 4beta-[(4' '-benzamido)-amino]-4'-o-demethyl-epipodophyllotoxin derivatives | Q40509569 |
| | Genetic evidence for involvement of two distinct nonhomologous end-joining pathways in repair of topoisomerase II-mediated DNA damage | Q40555008 |
| | Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic | Q40743946 |
| | Role of glutathione depletion and reactive oxygen species generation in apoptotic signaling in a human B lymphoma cell line. | Q40748964 |
| | Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line | Q41055485 |
| | Recent advances in the discovery and development of topoisomerase inhibitors as antitumor agents | Q41521938 |
| | Hypersensitivity of nonhomologous DNA end-joining mutants to VP-16 and ICRF-193: implications for the repair of topoisomerase II-mediated DNA damage | Q42169313 |
| | Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells | Q42828773 |
| | Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. | Q44215095 |
| | Expression of phosphorylated histone H2AX as a surrogate of cell killing by drugs that create DNA double-strand breaks. | Q44542313 |
| | Restoration of growth arrest by p16INK4, p21WAF1, pRB, and p53 is dependent on the integrity of the endogenous cell-cycle control pathways in human glioblastoma cell lines | Q46047054 |
| | Topoisomerase II inactivation prevents the completion of DNA replication in budding yeast | Q46526137 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | renal carcinoma | Q18556333 |
| P304 | page(s) | e112220 | |
| P577 | publication date | 2014-11-05 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | NPRL-Z-1, as a new topoisomerase II poison, induces cell apoptosis and ROS generation in human renal carcinoma cells | |
| P478 | volume | 9 | |